NIPPON follow-up: Shorter dual antiplatelet therapy stands the test of time (DAPT)

August 28, 2017

Barcelona, Spain - 28 Aug 2017: Three year follow-up of patients who received dual antiplatelet therapy (DAPT) after placement of a drug-eluting stent (DES) shows that a short course of the therapy continues to be as beneficial as a longer course.

The long-term follow-up of patients in the NIPPON (NoborI dual antiplatelet therapy as aPPrOpriate DuratioN) study is presented today at ESC Congress 2017.

"These findings support and strengthen the evidence for short-term DAPT after DES deployment, and may help confirm that clinical benefits of extended DAPT are reduced in patients with newer generation DES," said Prof Masato Nakamura MD, PhD, from the Division of Cardiovascular Medicine at Toho University Ohashi Medical Center, in Tokyo Japan.

"The findings are important because shorter duration of therapy is less expensive and could theoretically reduce the risk of side-effects," noted Prof Nakamura.

Initial results of NIPPON, presented last year at ESC Congress, showed no significant differences in rates of a composite efficacy and safety endpoint in patients randomised to either 6 or 18-month durations of DAPT (J Am Coll Cardiol Interv 2017; 10: 1189-98).

"For the long-term follow-up we wanted to evaluate efficacy and safety individually," said Prof Nakamura explaining that efficacy endpoints included cardiac death, myocardial infarction, stroke, and definite or probable stent thrombosis, while the safety endpoint was major bleeding.

Among the 3,307 patients included in the 3-year follow-up, there were no statistically significant differences between those treated for 6 versus 18 months in either safety or efficacy endpoints, although there was a numerically higher rate of better outcomes in the long-term DAPT group (HR: 1.53, 95%CI: 0.81-2.87, p=0.17), he reported.

To explore this trend, the researchers did subgroup analyses to see if any particular groups fared better with longer therapy. They discovered that in patients aged 70-77 years with either diabetes or more severe coronary artery disease (based on a SYNTAX score above 23.3) the rate of efficacy events was zero percent in those on long-term therapy, but 18.8 percent in those on short-term therapy. These patients "represent a high-risk population for ischemic events who might be good candidates for prolonged DAPT," they concluded.

"In real-world practice, it is not easy to find the balance between risks and benefits of DAPT duration, and consensus criteria for individualisation therapy have not been established," said Prof Nakamura. "The present findings may provide some assistance, although it is essential to obtain confirmation by further investigation."
-end-


European Society of Cardiology

Related Safety Articles from Brightsurf:

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

How EU safety legislation has affected UK vapers
New research shows that vapers have been largely reassured by recent EU regulations, but some have been pushed to the black market for stronger hits.

Tunnel fire safety
With only minutes to respond, fire education really counts.

New study supports the safety of varenicline
A real-world study of over 600,000 adult participants without a history of depression has found that the stop-smoking medication varenicline (marketed as Chantix and Champix) does not appear to be associated with an increased risk of cardiovascular or neuropsychiatric hospitalization compared with nicotine replacement therapy (NRT).

Advancing frozen food safety: Cornell develops novel food safety assessment tool
New research funded by the Frozen Food Foundation developed a modeling tool to assist the frozen food industry with understanding and managing listeriosis risks.

'Safety signals' may help slow down anxiety
For as many as one in three people, life events or situations that pose no real danger can spark a disabling fear, a hallmark of anxiety and stress-related disorders.

UQ researcher carving a new path for skier safety
A spectacular stack on a ski slope in Canada has led to a University of Queensland researcher determining a simple modification that could improve skier safety on the snow.

Nanomaterial safety on a nano budget
A Rice University laboratory develops and shares a low-cost method to safely handle the transfer of bulk carbon nanotubes and other nanomaterials.

Drexel-developed safety climate scale helps fire departments reach safety goals
A new safety scale, that effectively measures the safety climate of a fire department, has been developed by researchers from Drexel's Dornsife School of Public Health, according to a paper published today in the journal Safety Science.

Safety of overlapping surgeries
Overlapping surgeries, in which more than one procedure is performed by the same surgeon working in different operating rooms, have raised concerns about potential adverse outcomes.

Read More: Safety News and Safety Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.